Know your risks – and options – this National Liver Awareness Month
October is National Liver Awareness Month and Liver Cancer Awareness Month, and advocacy organizations across the U.S., including the American Liver Foundation (ALF), are…
Cholangitis
PBC worst for life quality among autoimmune liver diseases: Study
Adults with autoimmune liver disease experience lower quality of life, especially those with primary biliary cholangitis (PBC), who report more fatigue, sleepiness, and pain…
Phase 2 trial of volixibat for PSC-related itching now fully enrolled
Enrollment is complete in the Phase 2b VISTAS clinical trial, which is testing the experimental oral treatment volixibat in people with itching due to…
PBC treatment Ocaliva leaves U.S. market amid safety concerns
Intercept Pharmaceuticals has voluntarily withdrawn Ocaliva (obeticholic acid), an oral therapy used to treat certain adults with primary biliary cholangitis (PBC), from…
Groups unite to fight liver disease during PBC Awareness Month
Members of the primary biliary cholangitis (PBC) community have come together in September as part of PBC Awareness Month to build support and share…
New trial data show saroglitazar works to ease liver damage in PBC
One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with…
Blood marker can predict liver function improvement in PBC
A blood marker of inflammation called lymphocyte-to-monocyte ratio (LMR) is an independent predictor of liver recompensation — when liver function improves with treatment despite permanent…
Chemomab, FDA align on key aspects of nebokitug development
Chemomab Therapeutics has aligned with U.S. regulators on several aspects of the late-stage development of nebokitug, its candidate therapy for primary sclerosing cholangitis (PSC),…
PSC raises colorectal cancer risk even without IBD
People with primary sclerosing cholangitis (PSC) have a six times higher risk of cancer affecting the large intestine or rectum, and that risk remained…
Adding Vitamin D boosts PBC treatment in clinical trial
Adding vitamin D to ursodeoxycholic acid (UDCA) treatment is superior to UDCA alone at reducing symptoms, liver damage markers, and liver scarring in previously untreated…
Recent Posts
- Know your risks – and options – this National Liver Awareness Month
- Enrollment complete in 2 Phase 2 trials testing hepatitis B treatment
- PBC worst for life quality among autoimmune liver diseases: Study
- Changes big and small can benefit those of us with MASH
- PFIC Awareness Day means… spotlighting the rare liver disease